Vaylen vs IVIM Health: Price, Protocols, and Patient Ratings
Vaylen vs IVIM Health: if you want the lowest advertised prepaid monthly rate, Vaylen starts semaglutide at $83.25/mo on a 12-month plan; if independent reviews and a structured protocol matter, IVIM Health highlights 4.9-star ratings and a proprietary GLP-1 ID protocol. Quick verdict: choose Vaylen for the lowest annualized prepaid pricing and multiple formats; choose IVIM Health for third-party ratings and a free, no-obligation consult.
See Vaylen pricing and formats
Direct comparison overview: pricing model and refunds
Vaylen posts annualized, prepaid pricing: semaglutide injections from $83.25/mo, oral semaglutide $99/mo, and tirzepatide $149/mo, each billed as a single upfront 12-month charge. Vaylen requires payment before clinician review but states a full refund for that billing cycle if a clinician declines. IVIM Health markets a different entry path: a free no-obligation consultation (a $75 value) and a promotional free-month code GIFT75; its published ongoing pricing includes $174/month after initial offers, with base listed rates such as $75/mo for compounded semaglutide plus a program fee. The critical difference is prepay-first with Vaylen versus consult-first with IVIM Health and promotional first-month offers.
What that means for buyers
Vaylen may appeal to decisive buyers willing to prepay a year to access lower monthly math. IVIM lowers upfront commitment via a free consult and promotional month before ongoing rates apply.
Get IVIM Health free consult and offer
Formats, molecules, and switching flexibility
Both providers work with compounded GLP-1 medications and offer semaglutide and tirzepatide. Vaylen sells three formats on one platform: weekly semaglutide injections, daily oral semaglutide tablets, and weekly tirzepatide, and emphasizes the ability for a clinician to switch formats without changing providers. IVIM Health offers compounded semaglutide and tirzepatide under a clinician-guided program and highlights weekly dose adjustments via its GLP-1 ID protocol. The distinction: Vaylen explicitly markets a needle-free tablet option on the same platform; IVIM emphasizes a structured titration protocol.
Explore Vaylen formats and needle-free option
Clinical claims, outcomes, and ratings
Vaylen’s pages reference average body weight loss figures tied to the same active ingredients as branded drugs, and assert clinician review within 24 hours and included telehealth consultations. IVIM Health highlights dual 4.9-star ratings on Google and Trustpilot and a proprietary claim that its GLP-1 ID protocol can accelerate weight loss by up to 40% compared to a selected trial; IVIM notes this is its protocol claim and not an independent head-to-head study. IVIM also cites peer-reviewed observational studies underlying some outcomes reporting. Both providers include qualifying language that compounded medications are not FDA-approved and have not undergone FDA review for safety, efficacy, or quality.
Logistics: shipping, fees, and memberships
Vaylen promises free discreet shipping in 1 to 3 business days and bundles clinician review and prescription fulfillment into the plan price with a stated $0 consultation fee. IVIM lists program fees (for example a $74.99/mo program fee mentioned on landing content) and promotional pricing such as a free-month membership with code GIFT75. IVIM discloses ongoing pricing that rises after introductory offers; Vaylen discloses that headline rates require full upfront payment for 12 months and does not publish terms for unused portions if a patient cancels mid-treatment.
Comparison table: five key criteria
| Criteria | Vaylen | IVIM Health |
|---|---|---|
| Starting published rate | $83.25/mo on 12-month semaglutide | $75/mo listed, promotional free month available |
| Billing model | Prepay 12 months in one charge; refund if clinician declines | Free consult and promotional month; ongoing monthly fee after intro |
| Formats offered | Weekly injection, daily oral tablet, weekly tirzepatide | Compounded semaglutide and tirzepatide with clinician titration |
| Clinical claims and evidence | Clinician review within 24 hours; product averages referenced on pages | 4.9-star Google and Trustpilot; proprietary GLP-1 ID protocol claims and observational studies cited |
| Regulatory note | Compounded medications not FDA-approved | Compounded medications not FDA-approved |
Regulatory and safety disclosures
Both Vaylen and IVIM Health state that their compounded medications are not FDA-approved finished products and have not been evaluated by the FDA for safety, effectiveness, or quality. IVIM additionally points to published observational studies and notes results may vary; Vaylen highlights that prescriptions are issued only when a licensed clinician determines treatment is medically appropriate and that compounded medications are prepared by licensed pharmacies.
Claim IVIM free month and consult
Choose based on what matters to you
Choose Vaylen if you prioritize the lowest advertised annualized prepaid monthly rate, want both injectable and needle-free oral semaglutide on one platform, and accept prepaying before clinician review with a stated refund if declined. Choose IVIM Health if third-party ratings and a clinician-guided GLP-1 ID protocol, plus a no-obligation free consultation and promotional free month, are more important to your decision.
Primary keyword: Vaylen vs IVIM Health